🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06824714
Recruiting Observational

Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System

NCT06824714 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing Medical University
Phase
Observational
Started
2024-01-01
Last updated
2025-02-13

Condition(s) studied

Large Vessel Vasculitis

Investigational drug(s) / intervention(s)

glucocorticoid, immunosuppressants, targeted therapy

glucocorticoid, immunosuppressants, targeted therapy: Drug intervention protocol will be determined by clinicians

Study summary

Large vessel vasculitis (LVV) causes vascular inflammation, leading to serious complications such as aneurysm formation and stroke. It is difficult to identify the inflammation of the vessel wall by the current imaging methods, thus affecting the timing of treatment and selection of treatment options. Improved examination methods to determine disease activity are highly needed to guide treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Clinically suspected or confirmed LVV and willing to undergo PET/MRA 2. Compliance with long-term follow-up 3. Sign informed consent. Exclusion Criteria: 1. Patients with other serious cardiovascular and cerebrovascular diseases, malignant tumors, infectious diseases, severe renal insufficiency. 2. Severe mental disorders, severe claustrophobia unable to cooperate with the examination. 3. Patients equipped with cardiac pacemaker, artificial heart valve, ferromagnetic vascular clamp after vascular surgery, aneurysm clamp, artificial cochlea, insulin pump and other drug dosage control devices, steel nail plate and other metal internal fixation, artificial joint, electronic eye, artificial eye. 4. Allergic to contrast medium. 5. Pregnant or lactating women. Withdrawal criteria: 1. Any exclusion criteria emerged during patient follow-up. 2. Voluntarily withdrew from the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Rheumatology and Immunology, Jiangsu Province Hospital, Nanjing Medical University Nanjing Jiangsu Recruiting

More Nanjing Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06824714 on ClinicalTrials.gov ↗ ← All trials in China